Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
Investing.com -- Boston Scientific (NYSE:BSX) reported fiscal Q4 2024 results that surpassed analyst expectations.
The company’s shares swung between gains and losses in premarket trading Wednesday.
The company reported earnings per share (EPS) of $0.70, topping analyst expectations of $0.66. Revenue for the period came in at $4.56 billion, also exceeding the consensus estimate of $4.41 billion.
"2024 was one of the best years in the history of Boston Scientific, fueled by our innovative portfolio, the launch of our FARAPULSE Pulsed Field Ablation System as well as significant clinical achievements and commercial excellence across businesses and regions," said Mike Mahoney, chairman and CEO of Boston Scientific.
"We have a strong foundation for growth, and I am incredibly grateful for our talented global team and the opportunity to continue transforming the lives of millions of patients around the world."
For the first quarter, the company expects adjusted EPS between $0.66 and $0.68, in line with the consensus estimate of $0.66. Net sales on a reported basis are projected to grow between 17% and 19% and approximately 14% to 16% on an organic basis.
For the full year 2025, Boston Scientific forecasts EPS in the range of $2.80 to $2.87, compared to the consensus estimate of $2.81.